Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.

被引：7
|
作者：
Tannir, Nizar M.
Signoretti, Sabina
Choueiri, Toni K.
McDermott, David F.
Motzer, Robert J.
George, Saby
Powles, Thomas
Donskov, Frede
Tykodi, Scott S.
Pal, Sumanta K.
Gupta, Saurabh
Lee, Chung-Wei
McHenry, M. Brent
Rini, Brian I.
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Roswell Pk Canc Inst, Buffalo, NY USA
[8] Queen Mary Univ London, Barts Canc Ctr, London, England
[9] Aarhus Univ Hosp, Aarhus, Denmark
[10] Univ Washington, Seattle, WA 98195 USA
[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[12] City Hope Natl Med Ctr, Duarte, CA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Plimack, E. R.
    Porta, C. G.
    George, S.
    Powles, T. B.
    Donskov, F.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M-O.
    Tomita, Y.
    Rini, B. I.
    McHenry, M. B.
    Lee, C-W.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
  • [2] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    ESMO OPEN, 2020, 5 (06)
  • [3] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    Flaifel, Abdallah
    Pignon, Jean-Christophe
    Ficial, Miriam
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Barthelemy, Philippe
    Tykodi, Scott S.
    Kocsis, Judit
    Ravaud, Alain
    Rodriguez-Cid, Jeronimo R.
    Pal, Sumanta K.
    Murad, Andre M.
    Ishii, Yuko
    Saggi, Shruti Shally
    McHenry, M. Brent
    Rini, Brian, I
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
  • [4] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Motzer, Robert
    Rini, Brian, I
    McDermott, David F.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael A.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Neiman, Victoria
    Bracarda, Sergio
    Tykodi, Scott S.
    Barthelemy, Philippe
    Leibowitz-Amit, Raya
    Plimack, Elizabeth R.
    Oosting, Sjoukje F.
    Redman, Bruce
    Melichar, Bohusiav
    Powles, Thomas
    Nathan, Paul
    Oudard, Stephan
    Pook, David
    Choueiri, Toni K.
    Donskov, Frede
    Grimm, Marc-Oliver
    Gurney, Howard
    Heng, Daniel Y. C.
    Kollmannsberger, Christian K.
    Harrison, Michael R.
    Tamita, Yoshihiko
    Duran, Ignacio
    Gruenwold, Viktor
    McHenry, M. Brent
    Mekan, Sabeen
    Tannir, Nizar M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
  • [6] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Atkins, Michael B.
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian, I
    Jiang, Ruiyun
    Federov, Viktor
    Lee, Chung-Wei
    Desilva, Heshani
    Tannir, Nizar M.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S17 - S18
  • [7] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Tannir, N. M.
    Albiges, L.
    Mcdermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Barthelemy, P.
    Plimack, E. R.
    Portat, C.
    George, S.
    Donskov, F.
    Atkins, M. B.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M. -o.
    Barrios, C.
    Tomita, Y.
    Castellano, D.
    Gruenwald, V.
    Rini, B. I.
    Jiang, R.
    Desilva, H.
    Fedorov, V.
    Lee, C. -w.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
  • [8] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [9] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
12345